SG11201811555VA - Novel natural protein and application thereof - Google Patents
Novel natural protein and application thereofInfo
- Publication number
- SG11201811555VA SG11201811555VA SG11201811555VA SG11201811555VA SG11201811555VA SG 11201811555V A SG11201811555V A SG 11201811555VA SG 11201811555V A SG11201811555V A SG 11201811555VA SG 11201811555V A SG11201811555V A SG 11201811555VA SG 11201811555V A SG11201811555V A SG 11201811555VA
- Authority
- SG
- Singapore
- Prior art keywords
- protein
- sdss1
- oligomer
- accumulation
- oxidation
- Prior art date
Links
- 102000004169 proteins and genes Human genes 0.000 title abstract 13
- 108090000623 proteins and genes Proteins 0.000 title abstract 13
- 238000009825 accumulation Methods 0.000 abstract 2
- 230000015572 biosynthetic process Effects 0.000 abstract 2
- 230000003647 oxidation Effects 0.000 abstract 2
- 238000007254 oxidation reaction Methods 0.000 abstract 2
- 241000699670 Mus sp. Species 0.000 abstract 1
- 241000288906 Primates Species 0.000 abstract 1
- 102000040739 Secretory proteins Human genes 0.000 abstract 1
- 108091058545 Secretory proteins Proteins 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000001717 pathogenic effect Effects 0.000 abstract 1
- 229920000642 polymer Polymers 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 230000009758 senescence Effects 0.000 abstract 1
- 210000002966 serum Anatomy 0.000 abstract 1
- 230000004083 survival effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/861—Adenoviral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/867—Retroviral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0603—Embryonic cells ; Embryoid bodies
- C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0696—Artificially induced pluripotent stem cells, e.g. iPS
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Gastroenterology & Hepatology (AREA)
- Virology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
Abstract
The present application discloses protein, including sequence, acid operating and area sDSS protein. The sDSS1 protein is a secretory protein of higher primate, can be detected in human serum and CSF. The sDSS1 protein can be with oxidation protein under nonenzymatic condition to form polymer or with Aβ polypeptide to reduce formation of Aβ oligomer. The addition of sDSS1 protein to culture can the induced oxidation Aβ oligomer, oligomer glycosylated so to the against toxoproteins. sDSS1 can survival of senescence-accelerated mice significantly. The protein can be used to prevent and treat diseases by protein, protein, protein accumulation, protein or formation accumulation of other pathogenic proteins with similar features, and has important potential in biological medicine. <Figure 3a>
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610519038.9A CN107573412B (en) | 2016-07-04 | 2016-07-04 | Novel natural protein and application thereof |
| PCT/CN2017/090785 WO2018006750A1 (en) | 2016-07-04 | 2017-06-29 | Novel natural protein and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201811555VA true SG11201811555VA (en) | 2019-01-30 |
Family
ID=60911986
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201811555VA SG11201811555VA (en) | 2016-07-04 | 2017-06-29 | Novel natural protein and application thereof |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US10815282B2 (en) |
| EP (1) | EP3444270A4 (en) |
| JP (5) | JP2019513023A (en) |
| KR (2) | KR102602486B1 (en) |
| CN (2) | CN107573412B (en) |
| AU (3) | AU2017293023B2 (en) |
| BR (1) | BR112019000118A2 (en) |
| CA (1) | CA3029458A1 (en) |
| CL (1) | CL2019000012A1 (en) |
| CO (1) | CO2019000235A2 (en) |
| EA (1) | EA201990179A1 (en) |
| IL (2) | IL301949A (en) |
| MX (1) | MX2019000192A (en) |
| PH (1) | PH12018550214A1 (en) |
| SG (1) | SG11201811555VA (en) |
| WO (1) | WO2018006750A1 (en) |
| ZA (1) | ZA201900209B (en) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107573412B (en) | 2016-07-04 | 2021-04-27 | 上海清流生物医药科技有限公司 | Novel natural protein and application thereof |
| CN109913483A (en) * | 2017-12-12 | 2019-06-21 | 上海清流生物医药科技有限公司 | A kind of fermentation manufacturing technique of protein drug |
| CN109985230B (en) * | 2018-01-02 | 2023-10-17 | 上海普佑生物医药有限公司 | Application of protein in preparation of medicine for preventing and treating kidney diseases |
| CN109985231A (en) * | 2018-01-02 | 2019-07-09 | 上海清流生物医药科技有限公司 | A kind of application of albumen in the drug that preparation prevents and treats dementia |
| CN110004105B (en) * | 2018-01-05 | 2023-09-29 | 上海普佑生物医药有限公司 | Application of protein in cell culture |
| CN110302362B (en) * | 2018-03-20 | 2024-04-05 | 上海普佑生物医药有限公司 | Application of protein in preparing medicine for preventing and treating diabetes complication |
| CN110882378A (en) * | 2018-09-10 | 2020-03-17 | 上海清流生物医药科技有限公司 | Application of protein in preparing medicament for preventing and treating atherosclerosis and complications |
| IL311448A (en) * | 2021-09-15 | 2024-05-01 | Shanghai Puyou Biomedical Co Ltd | Polypeptide |
| CN115287276A (en) * | 2022-03-07 | 2022-11-04 | 兰州大学 | Application of SEM1 protein and engineered probiotic bacteria expressing SEM1 protein in preparation of medicines for treating and/or preventing heart diseases |
| WO2024056028A1 (en) * | 2022-09-15 | 2024-03-21 | Shanghai Puyou Biochemical Co., Ltd. | Analgesic polypeptide |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1947112B1 (en) * | 1999-04-09 | 2012-05-16 | Heska Corporation | Flea head, nerve cord, hindgut and malpighian tubule nucleic acid molecules, proteins and uses thereof |
| JP2004121445A (en) | 2002-10-01 | 2004-04-22 | Akira Sakai | Oxidation stress eliminating material, dialyzing liquid circulating circuit having the same and oxidation stress eliminating method |
| WO2010072228A1 (en) * | 2008-12-22 | 2010-07-01 | Xigen S.A. | Novel transporter constructs and transporter cargo conjugate molecules |
| EP2510361A4 (en) * | 2009-12-11 | 2013-07-17 | Purdue Research Foundation | Detection of oxidized polypeptides |
| CN102755317A (en) * | 2011-04-28 | 2012-10-31 | 中国人民解放军军事医学科学院放射与辐射医学研究所 | 2-indolone derivatives and application of pharmaceutically acceptable salts thereof to preparation of antioxidant medicines |
| CN107573412B (en) | 2016-07-04 | 2021-04-27 | 上海清流生物医药科技有限公司 | Novel natural protein and application thereof |
-
2016
- 2016-07-04 CN CN201610519038.9A patent/CN107573412B/en active Active
- 2016-07-04 CN CN202110372331.8A patent/CN113150105B/en active Active
-
2017
- 2017-06-29 KR KR1020217030992A patent/KR102602486B1/en active IP Right Grant
- 2017-06-29 JP JP2018551999A patent/JP2019513023A/en not_active Withdrawn
- 2017-06-29 KR KR1020187028456A patent/KR20180127382A/en not_active IP Right Cessation
- 2017-06-29 MX MX2019000192A patent/MX2019000192A/en unknown
- 2017-06-29 BR BR112019000118A patent/BR112019000118A2/en not_active IP Right Cessation
- 2017-06-29 WO PCT/CN2017/090785 patent/WO2018006750A1/en active Application Filing
- 2017-06-29 AU AU2017293023A patent/AU2017293023B2/en active Active
- 2017-06-29 EA EA201990179A patent/EA201990179A1/en unknown
- 2017-06-29 SG SG11201811555VA patent/SG11201811555VA/en unknown
- 2017-06-29 IL IL301949A patent/IL301949A/en unknown
- 2017-06-29 CA CA3029458A patent/CA3029458A1/en active Pending
- 2017-06-29 IL IL263987A patent/IL263987B2/en unknown
- 2017-06-29 EP EP17823562.8A patent/EP3444270A4/en active Pending
-
2018
- 2018-09-28 US US16/145,251 patent/US10815282B2/en active Active
- 2018-12-27 PH PH12018550214A patent/PH12018550214A1/en unknown
-
2019
- 2019-01-03 CL CL2019000012A patent/CL2019000012A1/en unknown
- 2019-01-11 ZA ZA2019/00209A patent/ZA201900209B/en unknown
- 2019-01-11 CO CONC2019/0000235A patent/CO2019000235A2/en unknown
-
2020
- 2020-03-17 JP JP2020046451A patent/JP2020114833A/en active Pending
- 2020-09-15 AU AU2020233647A patent/AU2020233647B2/en active Active
- 2020-09-22 US US17/028,769 patent/US11198712B2/en active Active
-
2021
- 2021-11-08 US US17/521,286 patent/US20220135631A1/en active Pending
-
2022
- 2022-04-25 JP JP2022071555A patent/JP2022101660A/en active Pending
- 2022-04-25 JP JP2022071556A patent/JP2022101661A/en active Pending
- 2022-04-25 JP JP2022071554A patent/JP7386923B2/en active Active
- 2022-05-27 AU AU2022203613A patent/AU2022203613B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201811555VA (en) | Novel natural protein and application thereof | |
| AU2018240515A1 (en) | Nucleic acids encoding CRISPR-associated proteins and uses thereof | |
| WO2016037154A8 (en) | Recombinant hiv-1 envelope proteins and their use | |
| WO2015158808A3 (en) | Recombinant host cell engineered to overexpress helper proteins | |
| PH12015501837B1 (en) | Manufacturing methods to control c-terminal lysine, galactose and sialic acid content in recombinant proteins | |
| SG10201809152QA (en) | Recombinant host cell for expressing proteins of interest | |
| WO2014164348A3 (en) | Modified caspase polypeptides and uses thereof | |
| MX2020011334A (en) | Metabolically optimized cell culture. | |
| WO2015031771A3 (en) | Administration of kynurenine depleting enzymes for tumor therapy | |
| PH12019500485A1 (en) | Anti-dengue virus antibodies, polypeptides containing variant fc regions, and methods of use | |
| NZ602317A (en) | Stabilized alpha-galactosidase and uses thereof | |
| MY193519A (en) | Method for decreasing immunogenicity of protein and peptide | |
| GB201303983D0 (en) | Drug and method for the prophylaxis of HIV infection and for the prophylaxis and treatment of diseases caused by or associated with HIV, including AIDS | |
| MX2016000393A (en) | Lysine-specific chemoenzymatic protein modifications using microbial transglutaminase. | |
| MX2016013631A (en) | Modified host cells and uses thereof. | |
| MY180183A (en) | Methods and compositions for preventing norleucine misincorporation into proteins | |
| MY173174A (en) | Short bio-active peptides for promoting wound healing | |
| WO2016019350A3 (en) | Microscale bioprocessing system and method for protein manufacturing from human blood | |
| WO2013109190A3 (en) | Cho-gmt recombinant protein expression | |
| WO2014145368A3 (en) | Modification and novel compositions of human secretoglobin proteins | |
| SA519401175B1 (en) | Phenylalanine-Free Protein for The Treatment of Phenylketonuria | |
| MX2015010887A (en) | Formulations and methods for increased recombinant protein production. | |
| MX2015011931A (en) | Enhanced expression of picornavirus proteins. | |
| RU2011133064A (en) | Recombinant Pork Chemotripsin | |
| Zhalehjoo et al. | The application of fig proteases (ficin) as a digestive drug |